AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis-Reference-Cited by-同舟云学术

AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis

Published:2008-04-22 Issue:14 Volume:17 Page:2132-2143
ISSN:1460-2083
Container-title:Human Molecular Genetics
language:en
Short-container-title:

Author:

Buj-Bello Anna,Fougerousse Françoise,Schwab Yannick,Messaddeq Nadia,Spehner Danièle,Pierson Christopher R.,Durand Muriel,Kretz Christine,Danos Olivier,Douar Anne-Marie,Beggs Alan H.,Schultz Patrick,Montus Marie,Denèfle Patrice,Mandel Jean-Louis

Publisher

Oxford University Press (OUP)

Subject

Genetics (clinical),Genetics,Molecular Biology,General Medicine

Link

http://academic.oup.com/hmg/article-pdf/17/14/2132/17244759/ddn112.pdf

Reference48 articles.

1. The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies;Wallgren-Pettersson;J. Med. Genet.,1995

2. MTM1 mutations in X-linked myotubular myopathy;Laporte;Hum. Mutat.,2000

3. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast;Laporte;Nat. Genet.,1996

4. Mutations in dynamin 2 cause dominant centronuclear myopathy;Bitoun;Nat. Genet.,2005

5. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset;Bitoun;Ann. Neurol.,2007

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meeting Report: 2023 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Therapy of Neuromuscular Diseases’;Journal of Neuromuscular Diseases;2024-09-03

2. A healthcare claims analysis to identify and characterize patients with suspected X-Linked Myotubular Myopathy (XLMTM) in the Brazilian Healthcare System;Orphanet Journal of Rare Diseases;2024-05-07

3. Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial;eBioMedicine;2024-01

4. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial;The Lancet Neurology;2023-12

5. Gene therapy for primary myopathies: literature review and prospects;Archives de Pédiatrie;2023-11